Evidence for reduction of norepinephrine uptake sites in the failing human heart

Klinik III fur Innere Medizin, Universitat zu Koln, Germany.

OBJECTIVES. This study investigated the role of neuronal uptake of norepinephrine (uptake-1) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes. BACKGROUND. Several beta-adrenergic neuroeffector defects occur in heart failure. Whether an alteration in norepinephrine uptake-1 occurs is still unresolved. METHODS. The role of norepinephrine uptake-1 was studied in electrically stimulated (1 Hz, 37 degrees C) human ventricular cardiac preparations and isolated myocardial membranes. RESULTS. The effectiveness of norepinephrine in increasing the force of contraction was decreased in relation to the degree of heart failure. In contrast, the potency of norepinephrine was increased in failing hearts (New York Heart Association functional class IV) in relation to the concentrations producing 50% of the maximal effect (EC50). The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). CONCLUSIONS. In human heart failure, there is a presynaptic defect in the sympathetic nervous system, leading to reduced uptake-1 activity. This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. The pathophysiologic consequences could be an increased synaptic concentration of norepinephrine predisposing to adenylyl cyclase desensitization.

This article has been cited by other articles:

				J. S. Floras Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 375 - 385. [Abstract] [Full Text] [PDF]

				O. E. Osadchii, G. R. Norton, R. McKechnie, D. Deftereos, and A. J. Woodiwiss Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1898 - H1905. [Abstract] [Full Text] [PDF]

				E. Vanoli and P. B. Adamson What does the future hold for the management of chronic heart failure? Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C51 - C57. [Abstract] [Full Text] [PDF]

				S. J. Buss, J. Backs, M. M. Kreusser, S. E. Hardt, C. Maser-Gluth, H. A. Katus, and M. Haass Spironolactone Preserves Cardiac Norepinephrine Reuptake in Salt-Sensitive Dahl Rats Endocrinology, May 1, 2006; 147(5): 2526 - 2534. [Abstract] [Full Text] [PDF]

				C.-s. Liang, W. Mao, C. Iwai, S. Fukuoka, and S. Y. Stevens Cardiac sympathetic neuroprotective effect of desipramine in tachycardia-induced cardiomyopathy Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H995 - H1003. [Abstract] [Full Text] [PDF]

				F. A. Recchia and M. Giacca Targeted Uptake-1 Carrier to Rescue the Failing Heart Circ. Res., October 28, 2005; 97(9): 847 - 849. [Full Text] [PDF]

				G. Munch, K. Rosport, A. Bultmann, C. Baumgartner, Z. Li, L. Laacke, and M. Ungerer Cardiac Overexpression of the Norepinephrine Transporter Uptake-1 Results in Marked Improvement of Heart Failure Circ. Res., October 28, 2005; 97(9): 928 - 936. [Abstract] [Full Text] [PDF]

				J. Backs, E. Bresch, M. Lutz, A. V. Kristen, and M. Haass Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats Cardiovasc Res, August 1, 2005; 67(2): 283 - 290. [Abstract] [Full Text] [PDF]

				K. Leineweber, P. Rohe, A. Beilfuss, C. Wolf, H. Sporkmann, H. Bruck, H.-G. Jakob, G. Heusch, T. Philipp, and O.-E. Brodde G-protein-coupled receptor kinase activity in human heart failure: Effects of {beta}-adrenoceptor blockade Cardiovasc Res, June 1, 2005; 66(3): 512 - 519. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, I. J. Kopin, and D. S. Goldstein Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine Pharmacol. Rev., September 1, 2004; 56(3): 331 - 349. [Abstract] [Full Text] [PDF]

				B.-i. Kato, T. Nozawa, N. Igarashi, M. Nonomura, N. Fujii, A. Igawa, H. Asanoi, Y. Yamada, M. Inoue, and H. Inoue Discrepant Recovery Course of Sympathetic Neuronal Function and {beta}-Adrenoceptors in Rat Hearts After Reperfusion Following Transient Ischemia J. Nucl. Med., June 1, 2004; 45(6): 1074 - 1080. [Abstract] [Full Text] [PDF]

				A. El-Armouche, O. Zolk, T. Rau, and T. Eschenhagen Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure Cardiovasc Res, December 1, 2003; 60(3): 478 - 487. [Abstract] [Full Text] [PDF]

				K. Mardon, O. Montagne, N. Elbaz, Z. Malek, A. Syrota, J.-L. Dubois-Rande, M. Meignan, and P. Merlet Uptake-1 Carrier Downregulates in Parallel with the {beta}-Adrenergic Receptor Desensitization in Rat Hearts Chronically Exposed to High Levels of Circulating Norepinephrine: Implications for Cardiac Neuroimaging in Human Cardiomyopathies J. Nucl. Med., September 1, 2003; 44(9): 1459 - 1466. [Abstract] [Full Text] [PDF]

				M. K. Hahn, D. Robertson, and R. D. Blakely A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters J. Neurosci., June 1, 2003; 23(11): 4470 - 4478. [Abstract] [Full Text] [PDF]

				U. Sung, S. Apparsundaram, A. Galli, K. M. Kahlig, V. Savchenko, S. Schroeter, M. W. Quick, and R. D. Blakely A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity J. Neurosci., March 1, 2003; 23(5): 1697 - 1709. [Abstract] [Full Text] [PDF]

				K. Leineweber, K. Brandt, B. Wludyka, A. Beilfuss, K. Ponicke, I. Heinroth-Hoffmann, and O.-E. Brodde Ventricular Hypertrophy Plus Neurohumoral Activation Is Necessary to Alter the Cardiac {beta}-Adrenoceptor System in Experimental Heart Failure Circ. Res., November 29, 2002; 91(11): 1056 - 1062. [Abstract] [Full Text] [PDF]

				C.-S. Liang, Y. Himura, M. Kashiki, and S. Y. Stevens Differential pre- and postsynaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1863 - H1872. [Abstract] [Full Text] [PDF]

				K. Leineweber, T. Wangemann, C. Giessler, H. Bruck, S. Dhein, M. Kostelka, F.-W. Mohr, R.-E. Silber, and O.-E. Brodde Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1459 - 1465. [Abstract] [Full Text] [PDF]

				W. Raasch, T. Bartels, A. Gieselberg, A. Dendorfer, and P. Dominiak Angiotensin I-Converting Enzyme Inhibition Increases Cardiac Catecholamine Content and Reduces Monoamine Oxidase Activity via an Angiotensin Type 1 Receptor-Mediated Mechanism J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 428 - 434. [Abstract] [Full Text] [PDF]

				K. Leineweber, I. Heinroth-Hoffmann, K. Ponicke, G. Abraham, B. Osten, and O.-E. Brodde Cardiac {beta}-Adrenoceptor Desensitization Due to Increased {beta}-Adrenoceptor Kinase Activity in Chronic Uremia J. Am. Soc. Nephrol., January 1, 2002; 13(1): 117 - 124. [Abstract] [Full Text] [PDF]

				A. L'Abbate and G. Sambuceti Studying the neuronal side of the synaptic cleft. A tool for investigating the paradox of sympathetic nervous system and heart failure in dilated cardiomyopathy Eur. Heart J., September 1, 2001; 22(17): 1521 - 1522. [PDF]

				F.M. Bengel, B. Permanetter, M. Ungerer, S.G. Nekolla, and M. Schwaiger Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography Eur. Heart J., September 1, 2001; 22(17): 1594 - 1600. [Abstract] [PDF]

				P Acar, P Merlet, L Iserin, D Bonnet, D Sidi, A Syrota, and J Kachaner Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy Heart, June 1, 2001; 85(6): 692 - 696. [Abstract] [Full Text]

				U. Lotze, S. Kaepplinger, A. Kober, B. M. Richartz, D. Gottschild, and H. R. Figulla Recovery of the Cardiac Adrenergic Nervous System After Long-Term {beta}-Blocker Therapy in Idiopathic Dilated Cardiomyopathy: Assessment by Increase in Myocardial 123I-Metaiodobenzylguanidine Uptake J. Nucl. Med., January 1, 2001; 42(1): 49 - 54. [Abstract] [Full Text] [PDF]

				J. Mullenheim, B. Preckel, D. Obal, M. Heiderhoff, J. Hoff, V. Thamer, and W. Schlack Left Stellate Ganglion Block Has Only Small Effects on Left Ventricular Function in Awake Dogs Before and After Induction of Heart Failure Anesth. Analg., October 1, 2000; 91(4): 787 - 792. [Abstract] [Full Text] [PDF]

				C.-s. Liang, N. K. Rounds, E. Dong, S. Y. Stevens, J. Shite, and F. Qin Alterations by Norepinephrine of Cardiac Sympathetic Nerve Terminal Function and Myocardial {beta}-Adrenergic Receptor Sensitivity in the Ferret : Normalization by Antioxidant Vitamins Circulation, July 4, 2000; 102(1): 96 - 103. [Abstract] [Full Text] [PDF]

				H. Kawai, A. Mohan, J. Hagen, E. Dong, J. Armstrong, S. Y. Stevens, and C.-S. Liang Alterations in cardiac adrenergic terminal function and beta -adrenoceptor density in pacing-induced heart failure Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1708 - H1716. [Abstract] [Full Text] [PDF]

				H. Senzaki, N. Paolocci, Y. A. Gluzband, M. L. Lindsey, J. S. Janicki, M. T. Crow, and D. A. Kass {beta}-Blockade Prevents Sustained Metalloproteinase Activation and Diastolic Stiffening Induced by Angiotensin II Combined With Evolving Cardiac Dysfunction Circ. Res., April 14, 2000; 86(7): 807 - 815. [Abstract] [Full Text] [PDF]

				M. Ungerer, H.-J. Weig, S. Kubert, M. Overbeck, F. Bengel, A. Schomig, and M. Schwaiger Regional pre- and postsynaptic sympathetic system in the failing human heart -- regulation of {beta}ARK-1 Eur J Heart Fail, March 1, 2000; 2(1): 23 - 31. [Abstract] [Full Text] [PDF]

				O.-E. Brodde and M. C. Michel Adrenergic and Muscarinic Receptors in the Human Heart Pharmacol. Rev., December 1, 1999; 51(4): 651 - 690. [Abstract] [Full Text] [PDF]

				A. Cohen-Solal, Y. Esanu, D. Logeart, F. Pessione, C. Dubois, G. Dreyfus, R. Gourgon, and P. Merlet Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis J. Am. Coll. Cardiol., March 1, 1999; 33(3): 759 - 766. [Abstract] [Full Text] [PDF]

				F Hartmann, S Ziegler, S Nekolla, M Hadamitzky, M Seyfarth, G Richardt, and M Schwaiger Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography Heart, March 1, 1999; 81(3): 262 - 270. [Abstract] [Full Text]

				M. Bohm, M. Castellano, M. Flesch, C. Maack, M. Moll, M. Paul, F. Schiffer, and O. Zolk Chamber-Specific Alterations of Norepinephrine Uptake Sites in Cardiac Hypertrophy Hypertension, November 1, 1998; 32(5): 831 - 837. [Abstract] [Full Text] [PDF]

				K. Mardon, P. Merlet, A. Syrota, and B. Maziere Effects of 5-day hypoxia on cardiac adrenergic neurotransmission in rats J Appl Physiol, September 1, 1998; 85(3): 890 - 897. [Abstract] [Full Text] [PDF]

				T. Nozawa, A. Igawa, N. Yoshida, M. Maeda, M. Inoue, Y. Yamamura, H. Asanoi, and H. Inoue Dual-Tracer Assessment of Coupling Between Cardiac Sympathetic Neuronal Function and Downregulation of ß-Receptors During Development of Hypertensive Heart Failure of Rats Circulation, June 16, 1998; 97(23): 2359 - 2367. [Abstract] [Full Text] [PDF]

				M. Ungerer, F. Hartmann, M. Karoglan, A. Chlistalla, S. Ziegler, G. Richardt, M. Overbeck, H. Meisner, A. Schomig, and M. Schwaiger Regional In Vivo and In Vitro Characterization of Autonomic Innervation in Cardiomyopathic Human Heart Circulation, January 20, 1998; 97(2): 174 - 180. [Abstract] [Full Text] [PDF]

				B. Rundqvist, G. Eisenhofer, M. Elam, and P. Friberg Attenuated Cardiac Sympathetic Responsiveness During Dynamic Exercise in Patients With Heart Failure Circulation, February 18, 1997; 95(4): 940 - 945. [Abstract] [Full Text]

				B. Rundqvist, M. Elam, Y. Bergmann-Sverrisdottir, G. Eisenhofer, and P. Friberg Increased Cardiac Adrenergic Drive Precedes Generalized Sympathetic Activation in Human Heart Failure Circulation, January 7, 1997; 95(1): 169 - 175. [Abstract] [Full Text]

				M. Ungerer, A. Chlistalla, and G. Richardt Upregulation of Cardiac Uptake1 Carrier in Ischemic and Nonischemic Rat Heart Circ. Res., June 1, 1996; 78(6): 1037 - 1043. [Abstract] [Full Text]

				G. Eisenhofer, P. Friberg, B. Rundqvist, A. A. Quyyumi, G. Lambert, D. M. Kaye, I. J. Kopin, D. S. Goldstein, and M. D. Esler Cardiac Sympathetic Nerve Function in Congestive Heart Failure Circulation, May 1, 1996; 93(9): 1667 - 1676. [Abstract] [Full Text]

				M. Bohm, M. Castellano, E. Agabiti-Rosei, M. Flesch, M. Paul, and E. Erdmann Dose-Dependent Dissociation of ACE-Inhibitor Effects on Blood Pressure, Cardiac Hypertrophy, and ß-Adrenergic Signal Transduction Circulation, November 15, 1995; 92(10): 3006 - 3013. [Abstract] [Full Text]

				G. G. Neri Serneri, M. Boddi, P. A. Modesti, I. Cecioni, M. Coppo, L. Padeletti, A. Michelucci, A. Colella, and G. Galanti Increased Cardiac Sympathetic Activity and Insulin-Like Growth Factor-I Formation Are Associated With Physiological Hypertrophy in Athletes Circ. Res., November 23, 2001; 89(11): 977 - 982. [Abstract] [Full Text] [PDF]